Tool Guides Duration of Dual Antiplatelet Therapy After PCI

This article originally appeared here.
Share this content:
Tool Guides Duration of Dual Antiplatelet Therapy After PCI
Tool Guides Duration of Dual Antiplatelet Therapy After PCI

WEDNESDAY, March 30, 2016 (HealthDay News) -- A new prediction rule may inform which patients will see a benefit or harm from dual antiplatelet therapy beyond one year after percutaneous coronary intervention (PCI), according to a study published online March 29 in the Journal of the American Medical Association.

Robert W. Yeh, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues developed a clinical decision tool to identify patients expected to derive benefit versus harm from continuing thienopyridine beyond one year after PCI. The tool was based on stratification of patients participating in the DAPT (Dual Antiplatelet Therapy) study and was validated on patients in the PROTECT (Patient-Related Outcomes With Endeavor versus Cypher Stenting) trial.

The researchers found that continued thienopyridine versus placebo was associated with reduced ischemic events (P < 0.001) in the high-score group (score ≥2; 5,917 patients) compared with the low-score group (score <2, 5,731 patients; P = 0.07; interaction P < 0.001). Conversely, in the high-score group, continued thienopyridine was associated with smaller increases in bleeding (P = 0.26) compared with the low-score group (P < 0.001; interaction P = 0.02). However, among PROTECT patients in the validation cohort, the high-score patients (2,848) had increased ischemic events compared with the low-score patients, and no significant difference in bleeding.

"Among patients not sustaining major bleeding or ischemic events one year after PCI, a prediction rule assessing late ischemic and bleeding risks to inform dual antiplatelet therapy duration showed modest accuracy in derivation and validation cohorts," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »